-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 6, Luye Pharma announced that its self-developed anti-tumor innovative preparation-Goserelin Acetate Sustained Release Microspheres for Injection (LY01005) has completed a phase III clinical study for the treatment of prostate cancer in China, reaching the preset end point
.
The Phase III clinical trial of LY01005 is a randomized, open, positive drug-controlled clinical study to evaluate the effectiveness and safety of continuous intramuscular injection of LY01005 in the treatment of prostate cancer patients
.
The trial was randomized to receive LY01005 or control drug treatment at a ratio of 1:1, 3.
Phase III study results show that: LY01005 is injected intramuscularly once every 28 days at a dose of 3.
In addition to the field of prostate treatment, LY01005's phase III clinical study for the treatment of breast cancer in China is also underway
Note: The original text has been deleted